Natco Pharma gets USFDA EIR for Telangana facility
Hyderabad: Natco Pharma Limited has announced the successful closure of inspection with an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the pre-approval inspection conducted at its drug formulations facility in Kothur village, Telangana, India, during the period from 2nd March to 6th March 2020.
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.
With a modest beginning of operations as a single unit with 20 employees, Natco today has seven manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc.
Read also: Natco Pharma Net Profit Slips 35pc To Rs 104 Crore In Q3
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.